Medical devices, healthcare technology and the business of care
PMA approval · P220016

HepQuant SHUNT Liver Diagnostic Test

Hepquant, LLC · Decision date Jun 18, 2026

FDA DECISIONP220016

What did the FDA approve?

FDA records P220016 as an original PMA application. The recorded decision is approval, dated Jun 18, 2026.

FDA approval order statement

Approval for HepQuant SHUNT Liver Diagnostic TestThe HepQuant SHUNT Liver Diagnostic Test is designed for the quantitative detection of 13C-cholate and d4-cholate in human serum from blood samples collected after the intravenous administration of 13C-cholate and the oral ingestion of d4-cholate. The assay generates a Disease Severity Index (DSI) score from the clearance of 13C-cholate and d4-cholate. Sample analysis is conducted by the HepQuant Analytical Test Laboratory.A DSI score below the validated threshold can be used in patients with compensated cirrhosis (Child Pugh Class A), age 22 years or older, undergoing screening or surveillance for esophageal varices to identify those patients unlikely to have large esophageal varices. The DSI score aids in identifying patients unlikely to require esophagogastroduodenoscopy (EGD) at the time of testing.The HepQuant SHUNT Liver Diagnostic Test is not a stand-alone test and should be used in conjunction with other clinical and laboratory findings.
Regulatory pathway
Original PMA
Clinical specialty
Clinical Chemistry
Decision date
Jun 18, 2026

FDA source record

Regulatory record facts

Identifier
P220016
Regulatory pathway
Premarket approval application
Applicant
Hepquant, LLC
Product code
SIO
Decision code
APPR
Decision date
Jun 18, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Test for Esophageal Varices.

Applicant
Hepquant, LLC
Product code
SIO
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P220016 received

    Application receipt date recorded by FDA.

  2. P220016 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P220016. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Hepquant, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
12635 E. Montview Blvd., Suite 175l1, Aurora, CO, 80045

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records